Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 14/20 | 0.76 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.76 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8865804 | 0.89 | CYP11B1 (0.62) | CYP11B1CYP11B2 | |
| SCHEMBL6776094 | 0.86 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1FNTAFNTB | |
| SCHEMBL9642312 | 0.86 | CYP11B1 (1.00) | CYP11B1CYP11B2IDO1FNTAFNTB | |
| SCHEMBL7848245 | 0.85 | CYP11B1 (0.57) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL2789150 | 0.84 | CYP11B1 (0.61) | CYP11B1CYP11B2IDO1HPGDSFNTA | |
| SCHEMBL7086608 | 0.83 | CYP11B1 (0.79) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL8763109 | 0.82 | CYP11B1 (0.60) | CYP11B1CYP11B2IDO1HPGDSFNTA | |
| SCHEMBL7749564 | 0.82 | CYP11B1 (0.58) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL10283951 | 0.82 | CYP11B1 (0.60) | CYP11B1CYP11B2 | |
| SCHEMBL9267101 | 0.81 | CYP11B1 (0.58) | CYP11B1CYP11B2IDO1HPGDSFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691859-B2 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2010-04-06 | — | — | US | disclosed |
| EP-1382607-B1 | Prenyl transferase inhibitors | IPSEN PHARMA (FR) | 2009-08-19 | — | — | EP | disclosed |
| US-20080176835-A1 | Prenyl Transferase Inhibitors | BIOMEASURE, INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-7361656-B2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-04-22 | — | — | US | disclosed |
| US-7084135-B1 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2006-08-01 | — | — | US | disclosed |
| US-20060142275-A1 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1140942-B1 | PRENYL TRANSFERASE INHIBITORS | CONSEILS DE RECH SET D APPLIC (FR) | 2004-03-10 | — | — | EP | disclosed |
| EP-1382607-A2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-01-21 | — | — | EP | disclosed |
| EP-1140942-A2 | PRENYL TRANSFERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039130-A2 | PRENYL TRANSFERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2000-07-06 | — | — | WO | disclosed |
| US-5652257-A | ANTICARCINOGENIC | MERCK & CO., INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0783517-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176835-A1 | Prenyl Transferase Inhibitors | FNTA, FNTB, RCE1 | CYP11B1 256/4885CYP11B2 266/4885IDO1 3573/4885 |
| US-20060142275-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | CYP11B1 256/4885CYP11B2 266/4885IDO1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.